Previous close | 2.3900 |
Open | 2.3900 |
Bid | 2.3700 x 1300 |
Ask | 2.6000 x 1000 |
Day's range | 2.3000 - 2.4600 |
52-week range | 2.2800 - 9.4900 |
Volume | |
Avg. volume | 2,037,368 |
Market cap | 305.128M |
Beta (5Y monthly) | 2.61 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.1800 |
Earnings date | 31 Oct 2023 - 06 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.83 |
CAMBRIDGE, Mass., September 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on September 6, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 91,000 shares of its common stock to two new employees, consisting of stock options to purchase an aggregate of 45,500 shares of common stock and restricted stock units ("RSUs"), cove
CAMBRIDGE, Mass., September 07, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m. ET.
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -34.55% and 0.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?